autoimmune diseases
Clinical Research
Vifor Pharma's work is focused on finding treatment options for patients with less common diseases. Through clinical research, we are able to build evidence-based knowledge that will, once approved, help physicians effectively treat patients living with these diseases.
Scientific and operational expertise
Vifor Pharma's clinical research team has extensive large pharmaceutical company experience in the design and execution of clinical trials in various therapeutic categories. Through the extensive scientific and operational experience of our employees, we are able to work with experts to reach consensus on study designs in our relevant medical communities for specialized patient populations. Our research strictly adheres to clinical trial guidelines and ensures processes for high compliance and integrity of results.
Scaleable structure and specialist networks
Our clinical development infrastructure is scaleable to new therapeutic areas. Through our extensive specialist networks, we are able to garner the internal and external expertise required by disease area. Further, our human and financial resources allow in-depth focus on our areas of therapeutic interest. Vifor Pharma's initial research focus is in the area of autoimmune diseases which occur when the immune system attacks the body's own cells not recognizing them as "self" but rather as "non-self". There are more than 80 clinically distinct autoimmune diseases which affect more than 300 million people globally. Most of these conditions are highly debilitating and under-treated, creating significant social and financial burden.
Current area of focus: autoimmune disease
There are approximately 6,000 orphan illnesses worldwide for which there is a lack of adequate treatment options, and few, if any, treatments in development.
Vifor Pharma's work is focused on finding treatment options for patients with less common diseases. Through clinical research, we are able to build evidence-based knowledge that will, once approved, help physicians effectively treat patients living with these diseases.
Scientific and operational expertise
Vifor Pharma's clinical research team has extensive large pharmaceutical company experience in the design and execution of clinical trials in various therapeutic categories. Through the extensive scientific and operational experience of our employees, we are able to work with experts to reach consensus on study designs in our relevant medical communities for specialized patient populations. Our research strictly adheres to clinical trial guidelines and ensures processes for high compliance and integrity of results.
Scaleable structure and specialist networks
Our clinical development infrastructure is scaleable to new therapeutic areas. Through our extensive specialist networks, we are able to garner the internal and external expertise required by disease area. Further, our human and financial resources allow in-depth focus on our areas of therapeutic interest. Vifor Pharma's initial research focus is in the area of autoimmune diseases which occur when the immune system attacks the body's own cells not recognizing them as "self" but rather as "non-self". There are more than 80 clinically distinct autoimmune diseases which affect more than 300 million people globally. Most of these conditions are highly debilitating and under-treated, creating significant social and financial burden.
Current area of focus: autoimmune disease
There are approximately 6,000 orphan illnesses worldwide for which there is a lack of adequate treatment options, and few, if any, treatments in development.
CellCept
F. Hoffmann-La Roche (Roche)'s drug CellCept (mycophenolate mofetil/MMF), is a widely used transplantation medication that has proven effective in preventing organ rejection. In the United States , MMF is the leading branded transplant medicine for the prevention of rejection. With over a decade of clinical evidence, MMF has demonstrated that it provides potent immunosuppression, preventing organ rejection without the long-term toxic effects associated with other therapies.
Through the partnership with Roche, Vifor Pharma currently has two phase III MMF clinical trials underway for the treatment of three autoimmune diseases. MMF was first approved in 1995 for renal transplant, and the indications now also include heart and liver transplants.
MMF prevents immune reactions through a unique mode of action, which is highly relevant for many autoimmune disease patients. In 2003, Vifor Pharma and Roche signed a partnership agreement which gives Vifor Pharma exclusive worldwide* rights to develop and commercialize MMF in all autoimmune disease applications. (* ex Japan)
Through this partnership with Roche, Vifor Pharma currently has two phase III MMF clinical trials underway for the treatment of two autoimmune diseases: lupus nephritis and pemphigus vulgaris.
F. Hoffmann-La Roche (Roche)'s drug CellCept (mycophenolate mofetil/MMF), is a widely used transplantation medication that has proven effective in preventing organ rejection. In the United States , MMF is the leading branded transplant medicine for the prevention of rejection. With over a decade of clinical evidence, MMF has demonstrated that it provides potent immunosuppression, preventing organ rejection without the long-term toxic effects associated with other therapies.
Through the partnership with Roche, Vifor Pharma currently has two phase III MMF clinical trials underway for the treatment of three autoimmune diseases. MMF was first approved in 1995 for renal transplant, and the indications now also include heart and liver transplants.
MMF prevents immune reactions through a unique mode of action, which is highly relevant for many autoimmune disease patients. In 2003, Vifor Pharma and Roche signed a partnership agreement which gives Vifor Pharma exclusive worldwide* rights to develop and commercialize MMF in all autoimmune disease applications. (* ex Japan)
Through this partnership with Roche, Vifor Pharma currently has two phase III MMF clinical trials underway for the treatment of two autoimmune diseases: lupus nephritis and pemphigus vulgaris.
Clinical Trials
Vifor Pharma's current research is evaluating MMF, a transplant medication used to prevent organ rejection, for the treatment of two autoimmune diseases:
Lupus nephritis (LN)
Myasthenia gravis (MG)
Pemphigus vulgaris (PV)
Vifor Pharma's current research is evaluating MMF, a transplant medication used to prevent organ rejection, for the treatment of two autoimmune diseases:
Lupus nephritis (LN)
Myasthenia gravis (MG)
Pemphigus vulgaris (PV)
Medical Information
Vifor Pharma has a toll-free call number to respond to enquiries about the use of Mycophenolate Mofetil (MMF) in autoimmune diseases. Note: MMF is not approved, nor has it been found to be safe or effective for any autoimmune purposes by any regulatory body.
The medical information advisors are located at our offices in Victoria, Canada and Bagshot, United Kingdom, and are available from 09:00-01:00 Greenwich Meridian Time (GMT).
To speak with one of the advisors at no charge, please use the following toll-free number and your call will be automatically transferred to the appropriate centre.
Toll Free Number: +800 111-25252*
* This toll free number is available in Australia, Canada, China, Eire, France, Germany, Italy, Singapore, Spain, Sweden, UK and USA. The '+' in front of a toll-free phone number indicates the need to dial a local international access number. These are: Australia 0011, Canada 011, China 00, Eire 00, France 00, Germany 00, Italy 00, Singapore 001, Spain 00, Sweden 00, USA 011 (e.g.From the USA call 011 800 111 25252).
Alternatively, our medical information advisors can be reached via the following phone numbers:
During the hours of 09:00-17:00 GMT call: +44 1276-853-605 (UK)
During the hours of 17:00-01:00 GMT call: +1 250-744-2488 (Canada)
or on e-mail:
medinfo@viforpharma.com
Please note that these call numbers are for enquiries only. If you are a patient and require medical attention, please see your physician immediately or go to your nearest hospital or medical clinic. If you are a health care professional wishing to report an adverse event to a medication, please contact the Vifor Pharma Safety Hotline at +1 250-217-1051 in Victoria, B.C., Canada.
Vifor Pharma has a toll-free call number to respond to enquiries about the use of Mycophenolate Mofetil (MMF) in autoimmune diseases. Note: MMF is not approved, nor has it been found to be safe or effective for any autoimmune purposes by any regulatory body.
The medical information advisors are located at our offices in Victoria, Canada and Bagshot, United Kingdom, and are available from 09:00-01:00 Greenwich Meridian Time (GMT).
To speak with one of the advisors at no charge, please use the following toll-free number and your call will be automatically transferred to the appropriate centre.
Toll Free Number: +800 111-25252*
* This toll free number is available in Australia, Canada, China, Eire, France, Germany, Italy, Singapore, Spain, Sweden, UK and USA. The '+' in front of a toll-free phone number indicates the need to dial a local international access number. These are: Australia 0011, Canada 011, China 00, Eire 00, France 00, Germany 00, Italy 00, Singapore 001, Spain 00, Sweden 00, USA 011 (e.g.From the USA call 011 800 111 25252).
Alternatively, our medical information advisors can be reached via the following phone numbers:
During the hours of 09:00-17:00 GMT call: +44 1276-853-605 (UK)
During the hours of 17:00-01:00 GMT call: +1 250-744-2488 (Canada)
or on e-mail:
medinfo@viforpharma.com
Please note that these call numbers are for enquiries only. If you are a patient and require medical attention, please see your physician immediately or go to your nearest hospital or medical clinic. If you are a health care professional wishing to report an adverse event to a medication, please contact the Vifor Pharma Safety Hotline at +1 250-217-1051 in Victoria, B.C., Canada.